Super Studienergebnisse gegen Krebs in Phase 2!

SAN DIEGO, Oct. 12, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age‐related macular degeneration (AMD) and fibrotic diseases, today announced the initiation of a two cohort clinical trial sponsored by the National Cancer Institute (NCI), containing a Phase 2 portion evaluating the combination of TRC102 and Alimta® (pemetrexed) in patients with mesothelioma and a Phase 1b portion evaluating the combination of TRC102, Alimta and cisplatin in patients with solid tumors. TRC102, a novel small molecule inhibitor of the base excision repair (BER) pathway of chemotherapy resistance, is being studied in multiple ongoing clinical trials supported by the NCI in combination with multiple chemotherapeutics.

"TRC102 has shown promising data in multiple Phase 1 trials, and we are pleased that the NCI has chosen to move forward into Phase 2 testing," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "Previously completed clinical trials sponsored by TRACON, Case Cancer Center and the NCI have demonstrated that TRC102 can be safely combined with three separate chemotherapeutics - Alimta, Temodar® (temozolomide) and Fludara® (fludarabine).  This Phase 1b/2 study is part of a broad development program for TRC102 that includes a number of additional planned studies  including a Phase 2 trial in glioblastoma patients combining TRC102 with Temodar."